Live News EQUITY L impact Jul 02, 2026, 03:04 PM UTC

Crinetics Pharmaceuticals Shares Rise After UBS Initiates Coverage

() -- Crinetics Pharmaceuticals (CRNX) shares rose 8% on Thursday after UBS initiated coverage of the stock with a buy rating and a price target of $55 per share. Trading volume stood at nearly 1.4 million shares compared with a daily average of more than 1.2 million. Price: $41.75, Change: $+3.07, Percent Change: +7.94% Copyright © 2026. All rights reserved. does not provide investment advice. Unauthorized reproduction is strictly prohibited.

CRNX

SQUAWKNEWS 1 updates Updated Jul 02, 2026, 07:14 PM UTC

Story updates

07:14:28 PM UTC

SQUAWKNEWS

() -- Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 2.3%. The iShares Biotechnology ETF (IBB) climbed 2.1%. In corporate news, Crinetics Pharmaceuticals (CRNX) shares jumped 8% after UBS started coverage of the stock with a buy rating and a price target of $55 per share. Copyright © 2026. All rights reserved. does not provide investment advice. Unauthorized reproduction is strictly prohibited.

() -- Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 2.3%.

The iShares Biotechnology ETF (IBB) climbed 2.1%.

In corporate news, Crinetics Pharmaceuticals (CRNX) shares jumped 8% after UBS started coverage of the stock with a buy rating and a price target of $55 per share.

Unauthorized reproduction is strictly prohibited.